1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vista Pharmaceuticals Ltd.

Vista Pharmaceuticals Ltd.

BBSE:VISTAPH
5.48
INR
-0.45
(-7.59%)
-2.00EPS
376.08MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
5.53
5.5
6.15
8.88
9.76
10.3
7.5
0.34
0.11
0.27
2.36
1.71
0.88
- -
Basic EPS, GAAP
0.31
0.54
0.31
0.46
0.76
0.31
-1.21
-0.54
-0.24
-1.54
-1.03
-0.79
-1.96
- -
Free Cash Flow per Basic Share
-0.06
-1.45
-1.1
-0.39
-5.27
-0.78
-0.3
-1.89
-0.27
-0.81
-1.31
-1.26
-0.84
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
6.06
4.17
4.63
6.25
10.93
11.79
9.76
8.93
9.64
9.77
8.63
7.38
5.92
- -
Tangible Book Value per Share
6.06
4.17
3.49
4.86
8.96
9.13
6.62
6.33
7.04
7.23
6.59
5.83
4.37
- -
Basic Weighted Avg Shares
15
25
25
27
29
30
30
37
37
37
44
59
62
61
Sales/Revenue/Turnover
83
137
154
242
282
311
228
13
4
10
103
101
54
- -
Operating Margin (%)
5.38
12.08
11.26
12.26
22.77
1.59
-26.99
-194.04
-462.9
-386.81
-37.93
-47.31
-284.57
- -
Depreciation Expense
1
10
10
10
13
14
13
7
6
6
7
7
7
- -
Net Income, GAAP
5
14
8
12
22
9
-37
-20
-9
-57
-45
-46
-121
- -
Effective Tax Rate (%)
1.36
- -
7.66
- -
22.66
18.12
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
5.62
9.91
5.03
5.16
7.75
3.02
-16.16
-158.61
-225.19
-564.11
-43.86
-46.14
-223.38
- -
Working Capital
-24
-2
-18
66
126
125
53
60
109
97
-12
24
-13
- -
LT Debt
- -
- -
- -
60
59
60
55
87
74
52
29
24
18
- -
Total Equity
91
104
116
166
319
358
296
328
355
367
405
454
364
- -
Return on Invested Capital (%)
5.27
- -
4.52
- -
8.61
-0.23
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
5.27
- -
8.67
- -
9.33
4.94
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
5.27
13.94
7.03
8.85
9.02
2.78
-11.24
-6.43
-2.6
-15.69
-11.69
-10.83
-29.47
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
81
- -
LT Borrowings
- -
18
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
62
Market Capitalization
501
376
435

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
154
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
3
- -
Inventories
- -
110
- -
Total Current Liabilities
- -
166
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
81
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.54%
2.84%
-19.77%
Free Cash Flow
198.24%
40.32%
-30.19%
Net Income, GAAP
16.61%
124.72%
159.45%
Sales/Revenue/Turnover
92.49%
192.41%
-46.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
18
25
26
32
101
2026
15
15
24
- -
54
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.15
-0.16
-0.21
-0.24
-0.79
2026
-0.22
-0.42
-0.41
-0.91
-1.96
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Murali Meraga
Full Time Employees
30
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ravindra Co-operative Housing Society Hyderabad TS India 500033
IPO Date
Jul 21, 2003
Website
vistapharmaceuticals.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vista Pharmaceuticals Limited (VISTAPH.BO) manufactures and markets over-the-counter and prescription generic drug products consisting of tablets, capsules, and liquids across various therapeutic categories including anti-inflammatory, analgesic, anti-pyretic, antibiotics, gynecological range, iron supplements, pain management, gastrointestinal, and veterinary preparations; the company also provides third-party manufacturing services and sells formulations to related entities engaged in pharmaceutical production. Founded in 1992 and headquartered in Hyderabad, India, with a USFDA-approved manufacturing facility in India and a marketing and distribution center in the USA, Vista Pharmaceuticals initially focused on the United States market, becoming the first Indian company to secure USFDA approvals for OTC and prescription drugs in 1994 and commence exports in 1996, while its Indian facility received USFDA approval for ANDA products in June 2010. The company operates primarily in the pharmaceuticals and biotechnology sector, targeting domestic Indian markets and international exports particularly to the US, with recent activities including a board meeting scheduled for November 13, 2025, to consider financial results and an annual general meeting on September 30, 2025, where eight resolutions passed including audited financials adoption, reappointments of managing and whole-time directors, and auditors.